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Abstract Purpose: Glucose deg-
radation products (GDPs) are
precursors of advanced glycation end
products (AGEs) that cause cellular
damage and inﬂammation. We
examined the content of GDPs in
commercially available glucose-con-
taining infusion ﬂuids and
investigated whether GDPs are found
in patients’ blood. Methods: The
content of GDPs was examined in
infusion ﬂuids by high-performance
liquid chromatography (HPLC) anal-
ysis. To investigate whether GDPs
also are found in patients, we inclu-
ded 11 patients who received glucose
ﬂuids (standard group) during and
after their surgery and 11 control
patients receiving buffered saline
(control group). Blood samples were
analyzed for GDP content and car-
boxymethyllysine (CML), as a
measure of AGE formation. The
inﬂuence of heat-sterilized ﬂuids on
cell viability and cell function upon
infection was investigated. Results:
All investigated ﬂuids contained high
concentrations of GDPs, such as
3-deoxyglucosone (3-DG). Serum
concentration of 3-DG increased
rapidly by a factor of eight in patients
receiving standard therapy. Serum
CML levels increased signiﬁcantly
and showed linear correlation with
the amount of infused 3-DG. There
was no increase in serum 3-DG or
CML concentrations in the control
group. The concentration of GDPs in
most of the tested ﬂuids damaged
neutrophils, reducing their cytokine
secretion, and inhibited microbial
killing. Conclusions: These ﬁndings
indicate that normal standard ﬂuid
therapy involves unwanted infusion
of GDPs. Reduction of the content of
GDPs in commonly used infusion
ﬂuids may improve cell function, and
possibly also organ function, in
intensive-care patients.
Keywords Glucose  Infusion ﬂuids 
Toxicity  Advanced glycation end
products  Neutrophils  Innate
defense  Cell survival
Introduction
Isotonic glucose solutions are frequently used in intensive
care units (ICUs) to hydrate patients with acute disease or
after surgery. These commercially available ﬂuids contain
between 2.5% and 50% glucose and are heat-sterilized to
assure sterility of the products. Beyond hydration, these
sterile products provide calories. Dysregulated glucose
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strict glycemic control does not decrease infectious
morbidity, mortality, and length of stay in the ICU [1–4].
Glucose is seen as an inexpensive and secure source of
energy on the one hand, and as a harmful substance on the
other. What is perhaps less known is that the sterilization
process of these ﬂuid products leads to degradation of the
glucose to highly bioreactive glucose degradation prod-
ucts (GDPs).
Glucose is used as an osmotic agent in ﬂuids for
peritoneal dialysis (PD) to remove water from patients
with renal failure. Heat-sterilization of glucose-containing
PD ﬂuids promotes formation of a large number of GDPs
[5]. Several GDPs, such as 3-deoxyglucosone (3-DG),
3,4-dideoxyglucosone-3-ene (3,4-DGE), 5-hydro-
xymethyl-2-furaldehyde (5-HMF), and formaldehyde,
have been identiﬁed in PD ﬂuids [6, 7]. At the cellular
level, aldehydes disrupt cell signaling and cause extensive
damage to membrane lipids, cellular proteins, mitochon-
drial function, RNA, and DNA [8]. The most bioreactive
GDP in heat-sterilized PD solutions is 3,4-DGE [7]. This
toxic molecule was found to impair wound healing and to
induce apoptosis in human leukocytes and renal epithelial
cells [9–11]. Highly reactive GDPs, such as 3,4-DGE,
react instantly with different molecules, while others,
such as 3-DG and 5-HMF, remain in circulation [12].
After reaching the blood, GDPs bind to serum pro-
teins, which gives rise to advanced glycation end products
(AGE) [13]. AGEs are known to be involved in oxidative
stress and are associated with cardiovascular morbidity
and renal injury [14–16]. By using new manufacturing
techniques, PD solutions with low GDP content have been
produced [17, 18]. Such low-GDP PD solutions have been
shown to reduce serum AGE levels [13, 19] and decrease
serum 3-DG concentrations [20]. Several other clinical
studies have demonstrated that removal of GDPs from
ﬂuids leads to decreased inﬂammation, preserved kidney
function, and improved patient outcomes [19, 21–23].
In order to evaluate whether isotonic glucose-con-
taining infusion ﬂuids include toxic GDPs, we examined
the content of such substances in commercially available
glucose solutions and the effect they exhibited on neu-
trophil function. Furthermore, we analyzed patients’
blood for GDPs and CML after receiving standard glu-
cose-containing ﬂuid therapy in the postoperative setting
and compared the serum levels with those of patients
receiving buffered saline.
Methods
Fluids
Seven different brands of glucose-containing infusion
ﬂuids, which are routinely used in the ICU setting at Lund
University Hospital (Lund, Sweden), were investigated
(Table 1).
Patients
The study was approved by the Regional Ethical Review
Board (DNR 207/2007) of Lund University, Sweden.
After patients gave written informed consent to be
included in the study, 11 patients (6 women and 5 men)
receiving glucose-containing postoperative infusion ﬂuids
were included in the standard group, and 11 patients (6
women and 5 men) receiving buffered saline (Ringer’s
acetate) were included in the control group. Serum was
analyzed for GDPs and CML.
Studies of effects of GDPs on cell viability
and cell function
Cell viability was determined on isolated human neutro-
phils using the Thiazolyl blue tetrazolium bromide (MTT)
assay. As an experimental infection model, neutrophils
were infected with E. coli in the presence of GDPs or
Table 1 Content of GDPs in the investigated infusion ﬂuids
Number Name Company Glucose (%) GDP concentrations (lM)
b (mean ± SEM)
3-DG 3,4-DGE 5-HMF Formaldehyde
1 Glucos Fresenius 200 Fresenius Kabi AB 20 583 ± 9.7 59 ± 1.2 105 ± 7.7 19 ± 3.4
2 Glucos Fresenius 300 Fresenius Kabi AB 30 790 ± 21.7 56 ± 2.3 146 ± 7.1 34 ± 4.7
3 Rehydrex Fresenius Kabi AB 2.5 141 ± 0.7 22 ± 1.1 2 ± 0.2 17 ± 0.7
4 Glucos Baxter Baxter Medical AB 10 400 ± 9.7 50 ± 0.1 42 ± 1.6 10 ± 3.0
5 Glucos Baxter 25/50 Baxter Medical AB 2.5 123 ± 0.8 22 ± 0.2 2 ± 0.1 10 ± 1.1
6 Glucos BaxterViaﬂo Baxter Medical AB 5 238 ± 3.9 35 ± 0.6 17 ± 0.4 4 ± 1.2
7 Glucos Baxter Na40 K20 Baxter Medical AB 10 358 ± 5.4 59 ± 0.4 10 ± 0.3 21 ± 2.8
LC50
a 1,374 ± 47.9 47 ± 2.7 2,463 ± 64.2 44 ± 5.1
a LC50 is the concentration (lM) of GDPs that kills 50% of neutrophils
b Each value represents the mean ± standard error of the mean (SEM) (n = 3)
1214with infusion ﬂuids 2 and 3 or their respective sterile
ﬁltered control ﬂuids. Secretion of CXCL8 and interleu-
kin 6 (IL-6) by the infected neutrophils was quantiﬁed in
supernatants by enzyme-linked immunosorbent assay
(ELISA, RD Systems Europe). Capacity of neutrophil
microbial killing was measured by Fc-OxyBURST
(Invitrogen) according to the manufacturer’s instructions.
Detailed methods are described in the Electronic
Supplementary Material.
Results
GDPs found in all investigated infusion ﬂuids
In all of the tested ﬂuids, 3-DG, 3,4-DGE, 5-HMF, and
formaldehydewerefound(Table 1).Theconcentrationof3-
DG varied from 123 to 790 lM, of 3,4-DGE from 22 to
59 lM, of 5-HMF from 2 to 146 lM, and of formaldehyde
from 4 to 34 lM (Table 1). The concentration of methyl-
glyoxal was between 7 and 17 lM in ﬂuids 3 and 5–7, but
below the detection limit (1.0 lM) for the rest of the ﬂuids.
Acetaldehyde was only found in ﬂuids 3, 5, and 7, at very
low concentrations (1–2 lM) and close to the limit of
detection (\1.1 lM). Glyoxal concentration was below the
detectionlimit(3.4 lM)inmostoftheﬂuids,exceptﬂuid 3
that contained 31 lM. The concentrations of acetaldehyde,
methylglyoxal, and glyoxal were far lower than the LC50
values[7,24].TheconcentrationsofGDPsinsterileﬁltered
control ﬂuids were below the limit of detection.
GDPs in blood circulation
To ascertain whether the GDPs in glucose-containing
infusion ﬂuids could be found in patient blood circulation,
we investigated patients who received glucose-containing
ﬂuids (2.5% or 5%; numbers 5 and 6 in Table 1) within
their normal treatment (standard group) and compared
them with the control group who did not receive the glu-
cose-containing ﬂuids (Fig. 1). Levels of 3-DG, 3,4-DGE,
formaldehyde, and 5-HMF were measured in serum sam-
ples before infusion and after 0.5, 3, 6, and 9 h.
Before infusion the serum from all patients in the
standard group and in the control group contained normal
amountsof3-DG(approximately0.2 lM;Fig. 1;Table 2).
Theamountofserum3-DGinthestandardgroupincreased
immediately after infusion and declined slowly thereafter,
but had not reached the background level after 9 h. There
were some differences in individual serum levels of 3-DG
that could not be correlated to the amount of infusions,
clearance or the glucose content of the infused solutions.
There was no increase in the amount of serum 3-DG in the
controlgroup.Inaddition,wefoundasigniﬁcantdifference
between the groups during the infusion (P B 0.001) and at
theendoftheinfusion(P = 0.004).Theamountof5-HMF
in the standard group was at a normal concentration of
0.87 lM at the start of the study [25], increased steadily
afterinfusion,andreachedamaximumafter9 h(1.75 lM).
The serum concentrationof 5-HMFwas doubled at the end
of the study,butwe could notﬁndany statistical difference
between the groups. The amount of 5-HMF in the control
patients was below the limit of detection (1.0 lM)
throughoutthestudy.NoneofthemorereactiveGDPs,3,4-
DGE and formaldehyde, could be detected in the serum
from any patients.
Urinary GDP levels
Patients’ urine was collected throughout the study for
analysis of GDPs. Urine concentrations were then com-
pared with the amount of 3,4-DGE, 3-DG, and 5-HMF
that the patient group received during their therapy (see
Supplementary Fig. 1). An average patient in the standard
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Fig. 1 GDPs found in patient serum. Concentration of 3-DG (lM)
in serum of patients receiving glucose-containing infusion ﬂuids
and the control group: before infusion (0 h), mean values during
infusion (0.5–6 h), and at the end of infusion (9 h). The amount of
serum 3-DG increased rapidly after infusion of glucose-containing
infusion ﬂuids and did not reach the background level even after
9 h. The control group showed signiﬁcantly less variability of
serum 3-DG concentrations throughout the study. The statistical
difference between the groups was calculated with Mann–Whitney/
Student t test (ns nonsigniﬁcant, **P\0.01, ***P B 0.001)
Table 2 Serum concentrations (lM) of 3-DG in patients receiving
the glucose-containing infusion ﬂuids
Time (h) 0 0.5 3 6 9
Mean 0.19 1.54 0.48 0.50 0.50
SEM 0.02 0.19 0.10 0.09 0.08
P \0.001 0.002 0.006 \0.001
Signiﬁcance values were evaluated by one-way analysis of vari-
ance, Dunn comparisons test, and Mann–Whitney/Student t test
1215group received approximately 1.7 l infusion ﬂuids, which
contained 47 mg 3-DG, 7 mg 3,4-DGE, 2 mg 5-HMF,
and 0.4 mg formaldehyde. A tenth of the infused 3-DG
was found in the urine (4.5 mg, P = 0.0002), while the
amount of 5-HMF was four times higher (8.7 mg,
P = 0.0314) than the infused amount. We found no
5-HMF in the control group and on average 0.1 mg 3-DG
(P B 0.001 compared with the patient group, data not
shown). No 3,4-DGE or formaldehyde was found in urine.
AGE formation
We found a linear correlation between the infused 3-DG
and the increased CML formation (see Supplementary
Fig. 2) in the standard group. Nine hours after receiving
the initial treatment with infusion ﬂuids, the patients
showed a signiﬁcant increase of CML in serum (Fig. 2).
There was no increase in serum CML formation in the
control group (P B 0.001).
Heat-sterilized infusion ﬂuids reduce cell viability
The difference between infusion ﬂuids and control ﬂuids
is shown in Fig. 3. All ﬂuids were diluted to physiological
levels, as regards osmolarity and glucose, before they
were incubated with neutrophils (Fig. 3). The table
illustrates the content of GDPs in the diluted ﬂuids. Even
though the ﬂuids were substantially diluted, we found that
all but one of the investigated infusion ﬂuids signiﬁcantly
decreased cell viability compared with control ﬂuids.
Fluid 2, which originally contained the highest glucose
concentration and hence was diluted most (1:15), was the
one that was least harmful to neutrophils.
Dose response and lethal concentrations
To investigate the inﬂuence of GDPs on human cells,
neutrophilswereincubatedwithdifferentconcentrationsof
3,4-DGE, 3-DG, and 5-HMF. The lethal concentration of
GDPsthatkilled50%ofneutrophils(LC50)wascompared
withthe concentrationof GDPsfoundintheinfusionﬂuids
(Table 1).TheLC50valueforthemostreactiveGDPs,3,4-
DGE and formaldehyde, was 47 and 44 lM, respectively.
The majority of the investigated ﬂuids contained higher
concentrations of 3,4-DGE than 47 lM (Table 1). The
LC50 value for the less reactive molecules 3-DG and 5-
HMF was higher, 1,374 lM and 2,463 lM, respectively.
GDPs diminished the inﬂammatory response
The possible immunomodulatory role of GDPs was investi-
gated by measuring CXCL8 and IL-6 secretion upon
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serum concentrations in patients after receiving the infusion ﬂuids
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Fig. 3 Heat-sterilized infusion ﬂuids reduce cell viability. Com-
mercial heat-sterilized infusion ﬂuids were compared with the
control ﬂuids. The ﬁgure shows the difference in cell survival
between neutrophils treated with infusion ﬂuids or with sterile
ﬁltered control ﬂuids after 4 h of incubation. Mean of seven
separate experiments (±SEM). The ﬂuids were diluted to achieve
physiological concentrations of glucose (2%) and osmolarity
(285 mOsm/l). Concentrations of the GDPs in the diluted ﬂuids
are presented in the table in the ﬁgure. Statistical difference
between heat-sterilized infusion ﬂuids and control ﬂuids was
calculated with Mann–Whitney test/Student t test (*P\0.05,
**P\0.01, ***P\0.001, ns nonsigniﬁcant)
1216bacterial infection. E. coli infection of human neutrophils
induced secretion of both inﬂammatory cytokines (see Sup-
plementary Figs. 3 and 4). Normal background cytokine
production in uninfected neutrophils was 99 ± 4 pg/ml for
CXCL8 and 63 ± 20 pg/ml for IL-6. The background pro-
duction was set at zero in Supplementary Figs. 3 and 4. The
presence of GDPs, at the same concentration that was found
in an average infusion ﬂuid, clearly suppressed secretion of
both CXCL8 and IL-6. CXCL8 secretion was reduced by
57% with formaldehyde, 43% with 3,4-DGE, 33% with
3-DG, and 30% with 5-HMF. CXCL8 secretion was also
inhibitedwiththephysiologicallydilutedﬂuids 2and3(10%
and 38%, respectively) (see Supplementary Fig. 3), sug-
gesting a correlation with their content of GDPs. Neutrophil
IL-6secretionuponinfectionwassuppressedinthepresence
of formaldehyde,3,4-DGE,and3-DG(98%, 72%,and 59%,
respectively) compared with the positive control (Fig. 4). A
smaller inhibitory effect (28%) was found with 5-HMF. The
dilutedﬂuid 3,withthehighestcontentofGDPs,suppressed
IL-6 secretion by 73%, while the more diluted ﬂuid 2 was
less inhibitory (10%). The sterile ﬁltered control ﬂuids were
not found to inhibit neutrophil cytokine secretion.
To investigate the impact of GDPs on neutrophil
function, we measured the nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase-mediated secretion
of reactive oxygen species (ROS) from infected cells (see
Supplementary Fig. 4). Formaldehyde and 3,4-DGE sig-
niﬁcantly inhibited neutrophil microbial killing, by 43%
and 56%, respectively (P\0.001), while 3-DG and
5-HMF suppressed neutrophil microbial killing by 35%
and 23% (P\0.01). Neutrophil capacity to kill bacteria
was further inhibited with ﬂuid 3 (57%) and to a lesser
extent with ﬂuid 2 (10%). The sterile ﬁltered control
ﬂuids were not found to reduce neutrophil ROS secretion.
Discussion
All investigated glucose-containing infusion ﬂuids con-
tained high amounts of GDPs. Moreover, increased
concentrations of GDPs were found in blood circulation of
critically ill patients receiving standard postoperative ﬂuid
therapy. The amount of 3-DG in the serum of a healthy
human is approximately 0.2 lM[ 26], and increases two-
fold with disease such as diabetes and threefold in uremia
[26]. Before infusion, all patients had normal levels of
3-DG, but the concentration increased eightfold shortly
after infusion of glucose-containing infusion ﬂuids and did
not reach the background level even after 9 h. In contrast,
serum and urinary 3-DG levels were low in the control
patients who received buffered saline. This ﬁnding sug-
gests that the increased 3-DG found in serum of patients
receiving the standard postoperative ﬂuid therapy with
glucose originated from the high amounts of GDPs found
in these ﬂuids. We did not succeed in measuring the
amount of the more reactive GDPs, since these molecules
bind to proteins immediately after infusion and their
unbound concentrations were thus below the detection
limit [12]. Therefore, none of the infused 3,4-DGE was
detected in serum or in urine at the end of the study. Of the
infused 3-DG in the glucose-containing infusion ﬂuids, we
found 2% unbound in serum and only 9.6% in urine at the
end of our study. This means that 88% of the infused 3-DG
is gone, possibly bound to serum proteins, giving rise to
advanced glycation end products (AGEs) [13]. The serum
amount of 5-HMF doubled during the experiment, and
urinary secretion of this inert molecule increased fourfold.
One explanation for the increased 5-HMF concentration
might be that 3-DG is converted to 5-HMF through equi-
librium with the reactive 3,4-DGE [17, 18]. This could
explain the increased concentration of 5-HMF found in
urine, but it also demonstrates that 3-DG is a reservoir for
newly formed highly reactive 3,4-DGE.
There was a linear correlation between the amount of
infused3-DGandtheincreasedformationofCML,amarker
of AGE formation. Serum CML levels were low in the
control patients receiving buffered saline in this study. The
results are in good agreement with a recent publication by
Humpert et al. [27] showing that human serum albumin
(HSA) preparations for intravenous use contain high levels
of CML. Furthermore, they found that the infusion of these
CML-containing HSA preparations induced inﬂammation
and caused increased mortality in experimental peritonitis.
Furthermore,patientswithrenalfailureaccumulate3-DGin
serum due to impaired glucose metabolism and impaired
renal clearance. In two recent studies, hemodialysis (HD)
was showntoeffectively remove AGEs and 3-DG, whilean
increase of this molecule was observed after PD treatment
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Fig. 4 GDPs modulate the inﬂammatory response. Human neutro-
philswereinfectedwithE. colifor3 hinthepresenceofGDPs;3-DG
(307 lM), 3,4-DGE (48 lM), 5-HMF (16 lM) and formaldehyde (12
lM),orinthe presence ofinfusionﬂuids 2 and 3 withtheirrespective
controls (sf). E. coli-infected neutrophils were used as a positive
control. Uninfected cells were used as a negative control. The
presence of GDPs clearly suppressed secretion of both IL-6 and
CXCL8 (see Supplementary Fig. 3). The results are means from six
differentblooddonors.ThestatisticaldifferencebetweenGDP-treated
neutrophils and the positive control was calculated with Mann–
Whitney test/Student t test (*P\0.05, **P\0.01, ***P\0.001)
1217[28, 29]. This discrepancy was found to originate from the
ﬂuids used in the two modes of dialysis, i.e., PD ﬂuids
containhighamountsofGDPswhiletheHDﬂuidswerelow
inGDPs. Levels of AGEs are also knowntobe signiﬁcantly
elevated in postoperative complications after major opera-
tions such as surgical coronary artery revascularization and
renaltransplantation[30,31].Thepatientsinourstudywent
through a broad range of fairly uncomplicated operations,
but we found a restricted dissemination in serum CML
concentration.Thisindicatesthattheincreaseisrelatedtothe
infusion ﬂuids rather than to the surgery.
InfusionﬂuidscontaininghighlevelsofGDPsmayhave
systemic effects resulting from local cytotoxic activity on
blood vessels and blood cells, but also an indirect effect due
to enhanced systemic AGE formation. Increased 3-DG has
been shown to lead to a threefold increase in kidney lesions
after 3 days in a rat model [32]. Among the patients in our
study,weobservedaneightfoldincreaseinserum3-DGafter
receiving 1.7 l of GDP-containing infusion ﬂuid. In more
critically ill patients, it is not unusual for patients to receive
4 l of infusion ﬂuids every day, for 2 days or longer. The
more reactive GDP, formaldehyde, is connected to various
formsofcancerinhumans[33],andZwartet al.[34]showed
that rats exposed to 10 lM formaldehyde experienced a
signiﬁcant increase of cell turnover. However, the best way
to state the possible importance of GDPs in clinical practice
is perhaps to demonstrate what happens when they are
blocked. It is well known that reactive carbonyl compounds
play an important role in the development of diabetic com-
plications. A promising drug candidate for treatment of
diabeticnephropathyispyroxidamine,whichiscurrentlyon
the Food and Drug Administration (FDA) ‘‘fast track’’ for
phase IIIclinicaltrials[35].Pyroxidamineisascavengerfor
reactive carbonyl compounds such as 3-DG [36], and has
been shown in a phase II clinical study to ameliorate
nephropathy [37, 38], enhance whole-body insulin sensi-
tivity [39], increase creatinine clearance, and reduce
inﬂammation and formation of AGEs. These data suggest
thatsterilizationimprovementleadingtoGDPremovalfrom
infusion ﬂuids could be beneﬁcial for insulinsensitivity and
renal protection in intensive care patients.
Severely hyperglycemic patients typically suffer from
complications such as infections and decreased wound
healing. Recent studies have revealed that GDPs interfere
withcarbohydratemetabolism[40].Inthisstudy,wefound
that the most reactive GDP, 3,4-DGE, was present at con-
centrations that could decrease neutrophil viability and
affect cell function. Furthermore, neutrophil exposure to
GDPsortheinfusionﬂuidssigniﬁcantlyinhibitedsecretion
of cytokines involved in inﬂammatory conditions. These
ﬁndings show that normal postoperative ﬂuid treatment
involves infusion of potentially dangerous ﬂuids into
patients. These observations are in good agreement with a
study by Catalan et al. [11] showing that GDPs cause
neutrophil apoptosis. We analyzed the oxidative burst in
humanneutrophilstreatedwithGDPsorinfusionﬂuidsasa
functional measurement of neutrophil function upon bac-
terial infection. We found that the oxidative burst was
greatly inhibited both by GDPs and by the diluted infusion
ﬂuids.TheabilityofGDPstoimpairmicrobialkillingcould
thuscontributetotheinfectionsusceptibilityanddecreased
woundhealingthatareobservedinhyperglycemicpatients.
The results of this study indicate that normal postop-
erative ﬂuid treatment involves infusion of dangerously
high concentrations of GDPs. New manufacturing tech-
niques have reduced the amounts of GDPs in medical
ﬂuids, making these more biocompatible [17, 18]. It
seems evident that the same approach in manufacturing
should be introduced for ﬂuids for intravenous use.
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